KALV KalVista Pharmaceuticals Inc.

11.04
+0.3  (+3%)
Previous Close 10.74
Open 10.72
Price To Book 1.93
Market Cap 196,683,043
Shares 17,815,493
Volume 80,198
Short Ratio
Av. Daily Volume 123,625
Stock charts supplied by TradingView

NewsSee all news

  1. KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will

  2. KalVista Pharmaceuticals Reports Fiscal First Quarter Results

    – Phase 2 Clinical Trial of KVD900 for On-Demand Oral Treatment of Hereditary Angioedema (HAE) Attacks Expected to Complete in Late 2019 – – KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 2H 2019.
KVD001
Diabetic macular edema (DME)
Phase 2 data due late 2019.
KVD900
Hereditary Angioedema (HAE)
Phase 2 trial to be initiated 1H 2020. Indication TBA.
KVD824
Hereditary angioedema / Diabetic Macula Edema

Latest News

  1. KalVista Pharmaceuticals to Present at Cantor Global Healthcare Conference

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will

  2. KalVista Pharmaceuticals Reports Fiscal First Quarter Results

    – Phase 2 Clinical Trial of KVD900 for On-Demand Oral Treatment of Hereditary Angioedema (HAE) Attacks Expected to Complete in Late 2019 – – KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME)